Related references
Note: Only part of the references are listed.Prognostic significance of preoperative and postoperative CA 19-9 normalization in pancreatic adenocarcinoma treated with neoadjuvant therapy or surgery first
Timothy P. DiPeri et al.
JOURNAL OF SURGICAL ONCOLOGY (2022)
Role of CA 19.9 in the Management of Resectable Pancreatic Cancer: State of the Art and Future Perspectives
Alessandro Coppola et al.
BIOMEDICINES (2022)
Prognostic value of carcinoembryonic antigen and carbohydrate antigen 19-9 in periampullary cancer patients receiving pancreaticoduodenectomy
Sang Hun Park et al.
ASIAN JOURNAL OF SURGERY (2021)
A population-based study on incidence, treatment, and survival in ampullary cancer in the Netherlands
Evelien J. M. de Jong et al.
EJSO (2021)
Neoadjuvant therapy versus surgery first for ampullary carcinoma: A propensity score-matched analysis of the NCDB
Marissa Guo et al.
JOURNAL OF SURGICAL ONCOLOGY (2021)
Preoperative 2-[18F]FDG PET-CT aids in the prognostic stratification for patients with primary ampullary carcinoma
Pei-Ju Chuang et al.
EUROPEAN RADIOLOGY (2021)
Ampullary Carcinoma: An Overview of a Rare Entity and Discussion of Current and Future Therapeutic Challenges
Alessandro Rizzo et al.
CURRENT ONCOLOGY (2021)
Sustained Carbohydrate Antigen 19-9 Response to Neoadjuvant Chemotherapy in Borderline Resectable Pancreatic Cancer Predicts Progression and Survival
J. Bart Rose et al.
ONCOLOGIST (2020)
Determination of cutoff values for biomarkers in clinical studies
Sook Young Woo et al.
PRECISION AND FUTURE MEDICINE (2020)
Role of Adjuvant Multimodality Therapy After Curative-Intent Resection of Ampullary Carcinoma
Brett L. Ecker et al.
JAMA SURGERY (2019)
International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017
Shuji Isaji et al.
PANCREATOLOGY (2018)
Prognostic Value of Preoperative Serum Carcinoembryonic Antigen and Carbohydrate Antigen 19-9 After Resection of Ampullary Cancer
Tobias S. Schiergens et al.
JOURNAL OF GASTROINTESTINAL SURGERY (2017)
Association of Histopathologic Phenotype of Periampullary Adenocarcinomas With Survival
Jennifer L. Williams et al.
JAMA SURGERY (2017)
The characteristics and outcomes of small bowel adenocarcinoma: a multicentre retrospective observational study
Hiroyuki Sakae et al.
BRITISH JOURNAL OF CANCER (2017)
Influence of Preoperative Therapy on Short- and Long-Term Outcomes of Patients with Adenocarcinoma of the Ampulla of Vater
Jordan M. Cloyd et al.
ANNALS OF SURGICAL ONCOLOGY (2017)
Survival Benefit of Adjuvant Chemoradiotherapy in Patients With Ampulla of Vater Cancer A Systematic Review and Meta-analysis
Jeanny Kwon et al.
ANNALS OF SURGERY (2015)
Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer
Ching-Wei D. Tzeng et al.
HPB (2014)
CA19-9 in Potentially Resectable Pancreatic Cancer: Perspective to Adjust Surgical and Perioperative Therapy
Werner Hartwig et al.
ANNALS OF SURGICAL ONCOLOGY (2013)
Histomolecular Phenotypes and Outcome in Adenocarcinoma of the Ampulla of Vater
David K. Chang et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Carcinoma of the Ampulla of Vater: Patterns of Failure Following Resection and Benefit of Chemoradiotherapy
Manisha Palta et al.
ANNALS OF SURGICAL ONCOLOGY (2012)
Defined Clinical Classifications Are Associated with Outcome of Patients with Anatomically Resectable Pancreatic Adenocarcinoma Treated with Neoadjuvant Therapy
Ching-Wei D. Tzeng et al.
ANNALS OF SURGICAL ONCOLOGY (2012)
Effect of Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid or Gemcitabine vs Observation on Survival in Patients With Resected Periampullary Adenocarcinoma The ESPAC-3 Periampullary Cancer Randomized Trial
John P. Neoptolemos et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
Clinical significance of pathologic subtype in curatively resected ampulla of vater cancer
Woo Seok Kim et al.
JOURNAL OF SURGICAL ONCOLOGY (2012)
Lymph node ratio and preoperative CA 19-9 levels predict overall survival and recurrence-free survival in patients with resected pancreatic adenocarcinoma
Sabrina C. Wentz et al.
WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY (2012)
Serum CA 19-9 as a Marker of Resectability and Survival in Patients with Potentially Resectable Pancreatic Cancer Treated with Neoadjuvant Chemoradiation
Matthew H. G. Katz et al.
ANNALS OF SURGICAL ONCOLOGY (2010)
Histopathologic Features and Microsatellite Instability of Cancers of the Papilla of Vater and Their Precursor Lesions
Petra Ruemmele et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2009)
Prognosis of resected ampullary adenocarcinoma by preoperative serum CA19-9 levels and platelet-lymphocyte ratio
Richard A. Smith et al.
JOURNAL OF GASTROINTESTINAL SURGERY (2008)
Borderline resectable pancreatic cancer: The importance of this emerging stage of disease
Matthew H. G. Katz et al.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2008)
Carbohydrate antigen 19.9 accurately selects patients for laparoscopic assessment to determine resectability of pancreatic malignancy
C. M. Halloran et al.
BRITISH JOURNAL OF SURGERY (2008)
Carcinoma of the ampulla of vater: Factors influencing long-term survival of 127 patients with resection
Qi-lu Qiao et al.
WORLD JOURNAL OF SURGERY (2007)
Serum CA19-9 measurement increases the effectiveness of staging laparoscopy in patients with suspected pancreatic malignancy
S Connor et al.
DIGESTIVE SURGERY (2005)
Utility of tumor markers in determining resectability of pancreatic cancer
MG Schlieman et al.
ARCHIVES OF SURGERY (2003)
Patterns and predictors of failure after curative resections of carcinoma of the ampulla of Vater
T Todoroki et al.
ANNALS OF SURGICAL ONCOLOGY (2003)
Ampulla of vater cancers: T-stage and histological subtype but not Dpc4 expression predict prognosis
S Beghelli et al.
VIRCHOWS ARCHIV (2002)
Share Paper
